Home > Journals > Italian Journal of Vascular and Endovascular Surgery > Past Issues > Italian Journal of Vascular and Endovascular Surgery 2008 March;15(1) > Italian Journal of Vascular and Endovascular Surgery 2008 March;15(1):29-37

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

ITALIAN JOURNAL OF VASCULAR AND ENDOVASCULAR SURGERY

A Journal on Vascular and Endovascular Surgery


Official Journal of the Italian Society of Vascular and Endovascular Surgery
Indexed/Abstracted in: EMBASE, Scopus


eTOC

 

REVIEWS  


Italian Journal of Vascular and Endovascular Surgery 2008 March;15(1):29-37

language: English

Targeted renal therapy for contrast-induced nephropathy prevention and renal function preservation during vascular and endovascular procedures: a systematic review

Allie D. E., Patlola R. R., Hebert C. J., Ingraldi A., Lirtzman M. D., Wyatt C. H., Walker C. M.

Cardiovascular Institute of the South Lafayette, Louisiana, US


PDF  


Targeted renal therapy (TRT) is a novel emerging treatment where high-dose fenoldopam (FEN), a selective renal dopamine-1 receptor agonist and renal arteriolar vasodilator, is infused into both renal arteries via the US Food and Drug Administration (FDA)-approved 5-Fr bifurcated Benephit PV Catheter Infusion System. TRT has been shown to significantly increase the glomerular filtration rate by 25% vs placebo and IV-FEN (P<0.001), which may have important clinical implications in contrast-induced nephropathy prophylaxis and during vascular and endovascular surgical procedures.

top of page

Publication History

Cite this article as

Corresponding author e-mail